Skip to Content
Merck
All Photos(1)

Documents

SML0131

Sigma-Aldrich

ABT-751 hydrochloride

≥98% (HPLC)

Synonym(s):

N-[2-[(4-Hydroxyphenyl)amino]-3-pyridyl]-4-methoxybenzenesulfonamide hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C18H17N3O4S · HCl
CAS Number:
141450-48-8
Molecular Weight:
407.87
MDL number:
MFCD19440802
UNSPSC Code:
12352200
PubChem Substance ID:
329825181
NACRES:
NA.25

Quality Level

100

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

pink to purple

solubility

DMSO: ≥15 mg/mL

originator

Abbott

storage temp.

2-8°C

SMILES string

Cl.COc1ccc(cc1)S(=O)(=O)Nc2cccnc2Nc3ccc(O)cc3

InChI

1S/C18H17N3O4S.ClH/c1-25-15-8-10-16(11-9-15)26(23,24)21-17-3-2-12-19-18(17)20-13-4-6-14(22)7-5-13;/h2-12,21-22H,1H3,(H,19,20);1H

InChI key

KWQWWUXRGIIBAS-UHFFFAOYSA-N

Related Categories

Biochem/physiol Actions

ABT-751 is an orally bioavailable vascular disrupting agent (VDA) with a broad spectrum of antitumor activity. It binds to the colchicine binding site on β-tubulin and inhibits polymerization of microtubules.
ABT-751, a sulfonamide antimitotic agent, is under clinical trials to treat patients with various malignancies including refractory hematologic malignancies, non-small cell lung cancer (NSCLC), and colon cancer.

Features and Benefits

This compound was developed by Abbott. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302,H315,H319,H335

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Timothy J Jorgensen et al.
Cancer chemotherapy and pharmacology, 59(6), 725-732 (2006-09-13)
ABT-751 is an orally active antimitotic agent that is currently in Phase II clinical trials. This agent binds to the colchicine site on ss-tubulin and inhibits polymerization of microtubules. This disruption of microtubule dynamics leads to a block in the
Karen W L Yee et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 11(18), 6615-6624 (2005-09-17)
ABT-751 is an oral antimitotic agent that binds to the colchicine site on beta-tubulin. A phase 1 study was conducted to determine the maximum tolerated dose and toxicities of ABT-751 in patients with advanced myelodysplastic syndrome and relapsed or refractory
Tian Ma et al.
Chemotherapy, 58(4), 321-329 (2012-11-14)
ABT-751 is a novel antimitotic agent that exerted cytotoxic effects in preclinical studies. Carboplatin has efficacy in treating advanced non-small cell lung cancer (NSCLC) in combination with other drugs. Lung cancer cell lines were treated with ABT-751 and/or carboplatin to

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service